In my first article on the dual-action weight-loss shot (Mounjaro / tirzepatide) I covered the active ingredient and its mechanism. Now to the question patients ask most often: what really changes for real people? Here, as a cardiovascular surgeon, I summarise — in plain language — the benefits observed across the major clinical trials.
Disclaimer: This article is informational about a prescription drug; it is not medical advice. The decision to start this injection is always made together with the physician who examines you.
What actually changes in patients?
Because tirzepatide simultaneously affects pancreatic insulin cells, the appetite centre, gastric emptying, and fat-tissue metabolism, its benefits are not confined to one area. Weight, blood sugar, blood pressure, heart, sleep and liver — multiple systems can improve in parallel in the same patient. Five major clinical programmes mapped this across different patient groups:
- SURMOUNT — adults with obesity but without diabetes
- SURPASS — patients with type 2 diabetes
- SUMMIT — obesity + heart failure with preserved ejection fraction (HFpEF)
- SURMOUNT-OSA — moderate-to-severe obstructive sleep apnea
- SYNERGY-NASH — patients with metabolic dysfunction-associated steatohepatitis (MASH)
Below, the most concrete answer I can give for each.
Weight loss and quality of life
The SURMOUNT-1 trial followed 2,539 adults with obesity for 72 weeks. At the highest dose (15 mg), tirzepatide produced:
- average 22.5% reduction in body weight (≈ 22 kg in a 100-kg person)
- about 18 cm reduction in waist circumference
- visible easing of daily activities such as climbing stairs, bending, tying shoes
- a +24-point improvement in the IWQOL-Lite weight-related quality-of-life score
The clinical meaning: most patients describe achieving — for the first time after years of failed cycles — a durable downward weight curve (Jastreboff et al., NEJM 2022).
Type 2 diabetes: less need for medication
In type 2 diabetes patients, HbA1c (the 3-month average blood-sugar marker) drops by 1.7–2.0 percentage points. The everyday meaning of this:
- some patients can halve their insulin dose; some can stop insulin entirely
- need for other glucose-lowering drugs decreases or stops
- blood-sugar swings (highs and lows) noticeably smooth out
- long-term diabetes complication risks (eyes, kidneys, nerves) are reduced
Compared with the older drug from the same class (dulaglutide), tirzepatide produced about 2.5× greater weight loss (SURPASS programme).
Heart and vessels: lower mortality risk
This is the most strongly evidenced section. The SURPASS-CVOT trial followed 13,299 patients for four years:
- All-cause mortality 16% lower (HR 0.84; p = 0.002)
- Cardiorenal events 16% lower
- Equivalent safety on classical cardiovascular outcomes (heart attack, stroke)
So this injection does not just promote weight loss; it provides the first major evidence that it can extend life over the long term (Nicholls et al., NEJM 2025;393:2409–2420). For overweight patients with established cardiovascular disease and type 2 diabetes, this is a finding that shifts the standard of care.
HFpEF, sleep apnea, and fatty-liver disease
Three indications, one message: tirzepatide can improve multiple organs in parallel, beyond weight loss alone.
Heart failure with preserved ejection fraction (HFpEF)
The SUMMIT trial followed 731 patients with both obesity and HFpEF for 2 years. Tirzepatide reduced the risk of cardiovascular death + worsening heart failure by 38%; the 6-minute walk distance improved by +18.3 m, the inflammation marker hsCRP dropped by 37%, and quality of life (KCCQ) rose by +6.9 points (Packer et al., NEJM 2024).
Obstructive sleep apnea
In SURMOUNT-OSA, obese patients with moderate-to-severe OSA experienced a reduction of 25 events per hour in apnea-hypopnea index; systolic blood pressure dropped, daytime sleepiness improved, and some patients reached the threshold of being able to discontinue CPAP (Malhotra et al., NEJM 2024).
Fatty-liver disease (MASH / MAFLD)
The SYNERGY-NASH trial showed that, at 52 weeks, in patients with MASH and liver fibrosis, the proportion who achieved MASH resolution reached 44%, 56%, and 62% at the three doses (vs. 10% on placebo). Liver fat content dropped meaningfully (Loomba et al., NEJM 2024;391:299–310).
From a vascular surgeon”s perspective + Summary
In my vascular practice — varicose veins and venous disease, lymphedema and lipedema, peripheral arterial disease, chronic leg swelling — when a treatment can simultaneously act on weight, blood pressure, and systemic inflammation, we take it seriously. Tirzepatide eases all three loads, making it a powerful component of multidisciplinary management for patients with chronic venous insufficiency who are also struggling with obesity.
In summary, the principal benefits observed in patients on the dual-action weight-loss shot:
- Sustained, significant weight loss + meaningful gains in daily quality of life
- Major improvements in glycaemic control; reduced reliance on other medications
- 16% reduction in all-cause mortality in the high-risk group
- Heart failure, sleep apnea, fatty-liver disease: parallel multi-organ improvement
- For patients with vascular disease, a strong tool within a multidisciplinary plan
That said, these benefits are highly individual. Patients with the highest potential gain (high BMI + type 2 diabetes + cardiovascular risk + sleep apnea + fatty-liver disease coexisting) and those with higher risk of side effects (history of pancreatitis, MEN-2, etc.) must be evaluated case by case by a physician. Side effects and who needs to be cautious will be covered in detail in the third article of this series.
For an evaluation tailored to your health needs, please feel free to reach out via the contact page or read more on the about page.
Scientific References
- Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. DOI:10.1056/NEJMoa2206038 — nejm.org/doi/full/10.1056/NEJMoa2206038
- Nicholls SJ, Pavo I, Bhatt DL et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025;393:2409–2420. DOI:10.1056/NEJMoa2505928 — nejm.org/doi/full/10.1056/NEJMoa2505928
- Packer M, Zile MR, Kramer CM et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). N Engl J Med. 2024. DOI:10.1056/NEJMoa2410027 — nejm.org/doi/full/10.1056/NEJMoa2410027
- Malhotra A, Grunstein RR, Fietze I et al. Tirzepatide for Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024. DOI:10.1056/NEJMoa2404881 — nejm.org/doi/full/10.1056/NEJMoa2404881
- Loomba R, Hartman ML, Lawitz EJ et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391:299–310. DOI:10.1056/NEJMoa2401943 — nejm.org/doi/full/10.1056/NEJMoa2401943
- Tirzepatide. StatPearls. NCBI Bookshelf, 2024. ncbi.nlm.nih.gov/books/NBK585056
